MedTrace Logo

Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR

NCT04461223 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2020-07-08

No results posted yet for this study

Summary

using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2\* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF and extracellular volume(ECV) to evaluate the respective changes before and after anthracycline chemotherapy.

Conditions

Interventions

DIAGNOSTIC_TEST

contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)

CMR T1 mapping, T2mapping, T2\* mapping, LGE, ECV

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Eligibility

Min Age
8 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2021-12-01
Completion
2021-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04461223 on ClinicalTrials.gov